Alligator Bioscience: First-in-Class Bispecific Antibody, ALG.APV-527, Meets Important Trial Endpoints in Phase 1 Solid Tumor Trial
Colon cancer patient achieved stable disease and remained on study for more than six months, breast cancer patient remained on study for more than 11 monthsBiomarker analysis confirms immune activatio ...
Aptevo Therapeutics: First-in-Class Bispecific Antibody, ALG.APV-527, Meets Important Trial Endpoints in Phase 1 Solid Tumor Trial
Aptevo Therapeutics and Alligator Bioscience report favorable safety, tolerability and evidence of biological activity of ALG.APV-527, more than half of evaluable patients achieved stable diseaseColon ...
SpringWorks Therapeutics Announces Mirdametinib Data to be Presented at the 2024 Society for Neuro-Oncology (SNO) Annual Meeting
Data from the pivotal Phase 2b ReNeu trial demonstrate that patients with NF1-PN achieved deep responses and improvements in ...
MedPage Today18h
AMA Delegates Dive Into Water Bead Injuries; Patients' 'Scanziety' Over Test Results
"Despite how they're being marketed and perceived by the public, these water bead gel blasters can have devastating ...
Rising Kashmir18h
Breast Cancer: Risk factors, Diagnosis and Prevention
Breast cancer is among the most common malignant tumors affecting women worldwide, arising from a complex mix of genetic, ...